Supplementary Data from Bromodomain-Selective BET Inhibitors Are Potent Antitumor Agents against MYC-Driven Pediatric CancerP.J. Slavish, Philip M. Potter, Liying Chi et al.|Unknown|2023Cited by 0
Data from Bromodomain-Selective BET Inhibitors Are Potent Antitumor Agents against MYC-Driven Pediatric CancerP.J. Slavish, Philip M. Potter, Liying Chi et al.|Unknown|2023Cited by 0
Figure S5 from The MD Anderson Prostate Cancer Patient-derived Xenograft Series (MDA PCa PDX) Captures the Molecular Landscape of Prostate Cancer and Facilitates Marker-driven Therapy DevelopmentNallasivam Palanisamy, Nora M. Navone, Christopher J. Logothetis et al.|Unknown|2023Cited by 0
Figure S4 from The MD Anderson Prostate Cancer Patient-derived Xenograft Series (MDA PCa PDX) Captures the Molecular Landscape of Prostate Cancer and Facilitates Marker-driven Therapy DevelopmentNallasivam Palanisamy, Nora M. Navone, Jun Yang et al.|Unknown|2023Cited by 0
Figure S6 from The MD Anderson Prostate Cancer Patient-derived Xenograft Series (MDA PCa PDX) Captures the Molecular Landscape of Prostate Cancer and Facilitates Marker-driven Therapy DevelopmentNallasivam Palanisamy, Nora M. Navone, Jun Yang et al.|Unknown|2023Cited by 0